Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
暂无分享,去创建一个
A. Witteveen | A. Glas | L. Delahaye | P. Neven | H. Wildiers | G. Floris | F. Reyal | A. Smeets | K. Punie | Sileny N. Han | C. Laurent | L. Slembrouck | I. Nevelsteen | C. Helsmoortel | M. Bohec | S. Baulande | C. Reyes | D. Gentien | A. Rapinat | L. Mittempergher | V. Raynal | E. Van Nieuwenhuysen | M. Snel | I. Vanden Bempt | S. Vander Borght | L. Darrigues | A. Vincent Salomon | L. Jongen | G. Hoste | P. Sintubin | L. Vliegen | T. Cynober | S. Neijenhuis | Enora Laas Faron | Mylène Bohec | Audrey Rapinat
[1] René Bernards,et al. MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology. , 2019, The Journal of molecular diagnostics : JMD.
[2] F. Cardoso,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[4] C. Perou,et al. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. , 2018, Cancer treatment reviews.
[5] O. Myklebost,et al. Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples , 2018, PloS one.
[6] J. Bartlett,et al. Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores , 2017, PloS one.
[7] P. Whitworth,et al. Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) , 2017, Annals of Surgical Oncology.
[8] P. Nuciforo,et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. , 2017, The Lancet. Oncology.
[9] Benjamin Haibe-Kains,et al. The molecular basis of breast cancer pathological phenotypes , 2017, The Journal of pathology.
[10] P. Whitworth,et al. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping , 2016, Annals of Surgical Oncology.
[11] L. V. van't Veer,et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.
[12] Carlos Caldas,et al. Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer , 2016, Biomarker insights.
[13] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[14] A. Arance,et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.
[15] P. Whitworth,et al. Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) , 2014, Annals of Surgical Oncology.
[16] A. Luini,et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes , 2014, Breast Cancer Research.
[17] A. Glas,et al. MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. , 2014, The Journal of molecular diagnostics : JMD.
[18] Diederik Wehkamp,et al. Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature. , 2013, Personalized medicine.
[19] J. Wesseling,et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study , 2013, International journal of cancer.
[20] C. Perou,et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S Michiels,et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] E. van Limbergen,et al. Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] E. Mardis,et al. A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen , 2012, Clinical Cancer Research.
[24] Jason S. Carroll,et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response , 2012, Breast Cancer Research and Treatment.
[25] N. Esposito,et al. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas , 2012, Modern Pathology.
[26] L. V. van't Veer,et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.
[27] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[28] K. Bloom,et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.
[29] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[30] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[31] F. Cardoso,et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] A. Glas,et al. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial , 2017, Breast Cancer Research and Treatment.
[33] S. Mook,et al. Prognostic factors in breast cancer: one fits all? , 2011 .
[34] Yunlong Liu,et al. BMC Genomics BioMed Central Methodology article , 2005 .